Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival
To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy. Seventy-seven patients with primary breast c...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-03, Vol.12 (5), p.1501 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1501 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | Tinari, Nicola Lattanzio, Rossano Natoli, Clara Cianchetti, Ettore Angelucci, Domenico Ricevuto, Enrico Ficorella, Corrado Marchetti, Paolo Alberti, Saverio Piantelli, Mauro Iacobelli, Stefano |
| description | To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy.
Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study. TopoII and HER-2 were measured by immunohistochemistry in prechemotherapy and postchemotherapy (at the time of surgery) tumor specimens, and the value of their changes as predictors of relapse-free survival were evaluated by Kaplan-Meier and Cox proportional hazard regression analyses.
Neoadjuvant chemotherapy resulted in a significant reduction in the percentage of cells expressing TopoII (P < 0.0001). No significant change was observed for HER-2. TopoII and HER-2 expression before chemotherapy predicted tumor response to treatment. Changes in TopoII expression after chemotherapy were strongly associated with a poor relapse-free survival (P < 0.0001) in a Cox multivariate analysis adjusted for other clinicopathologic prognostic factors.
Changes in TopoII expression after anthracycline-based neoadjuvant chemotherapy is an independent predictor of a poor relapse-free survival in patients with breast cancer. Tumor cells displaying an increased TopoII expression after treatment may be responsible for relapses, and may, therefore, define a group of patients with anthracycline-resistant breast cancer. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16533774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16533774</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-557b0454cbff337fa87c716381f6ce07ff204a957cb071a90acd02a1b436be43</originalsourceid><addsrcrecordid>eNo1kM1KxDAURrNQnHH0FeS-QCFp0qazlMGfgQEXuh9u0hvboW1Ckg6OT29BXZ3Vd_g4V2wtuG4KrmS5YrcpnTgXSnB1w1airqTUWq3Z967D6ZMSeAfZB98nP1LERLDf4xA6BPoKkVLq_QT9BCYSpgx5Hn1MgC5ThIk8tqf5jFMG29Hoc7cowgWWYdvbnCDSgCFR4SIRpDme-zMOd-za4ZDo_o8b9v789LF7LQ5vL_vd46EIlVJFVWnDVaWscW757LDRVotaNsLVlrh2ruQKt5W2hmuBW4625SUKo2RtSMkNe_i1htmM1B5D7EeMl-N_AvkDqERakQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tinari, Nicola ; Lattanzio, Rossano ; Natoli, Clara ; Cianchetti, Ettore ; Angelucci, Domenico ; Ricevuto, Enrico ; Ficorella, Corrado ; Marchetti, Paolo ; Alberti, Saverio ; Piantelli, Mauro ; Iacobelli, Stefano</creator><creatorcontrib>Tinari, Nicola ; Lattanzio, Rossano ; Natoli, Clara ; Cianchetti, Ettore ; Angelucci, Domenico ; Ricevuto, Enrico ; Ficorella, Corrado ; Marchetti, Paolo ; Alberti, Saverio ; Piantelli, Mauro ; Iacobelli, Stefano</creatorcontrib><description>To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy.
Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study. TopoII and HER-2 were measured by immunohistochemistry in prechemotherapy and postchemotherapy (at the time of surgery) tumor specimens, and the value of their changes as predictors of relapse-free survival were evaluated by Kaplan-Meier and Cox proportional hazard regression analyses.
Neoadjuvant chemotherapy resulted in a significant reduction in the percentage of cells expressing TopoII (P < 0.0001). No significant change was observed for HER-2. TopoII and HER-2 expression before chemotherapy predicted tumor response to treatment. Changes in TopoII expression after chemotherapy were strongly associated with a poor relapse-free survival (P < 0.0001) in a Cox multivariate analysis adjusted for other clinicopathologic prognostic factors.
Changes in TopoII expression after anthracycline-based neoadjuvant chemotherapy is an independent predictor of a poor relapse-free survival in patients with breast cancer. Tumor cells displaying an increased TopoII expression after treatment may be responsible for relapses, and may, therefore, define a group of patients with anthracycline-resistant breast cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>PMID: 16533774</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - metabolism ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Cyclophosphamide - therapeutic use ; Disease-Free Survival ; DNA Topoisomerases, Type II - metabolism ; DNA-Binding Proteins - metabolism ; Drug Resistance, Neoplasm ; Epirubicin - therapeutic use ; Female ; Fluorouracil - therapeutic use ; Humans ; Mastectomy ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Invasiveness - pathology ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - metabolism ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - metabolism ; Prognosis ; Receptor, ErbB-2 - metabolism ; Stereoisomerism</subject><ispartof>Clinical cancer research, 2006-03, Vol.12 (5), p.1501</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16533774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tinari, Nicola</creatorcontrib><creatorcontrib>Lattanzio, Rossano</creatorcontrib><creatorcontrib>Natoli, Clara</creatorcontrib><creatorcontrib>Cianchetti, Ettore</creatorcontrib><creatorcontrib>Angelucci, Domenico</creatorcontrib><creatorcontrib>Ricevuto, Enrico</creatorcontrib><creatorcontrib>Ficorella, Corrado</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Alberti, Saverio</creatorcontrib><creatorcontrib>Piantelli, Mauro</creatorcontrib><creatorcontrib>Iacobelli, Stefano</creatorcontrib><title>Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy.
Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study. TopoII and HER-2 were measured by immunohistochemistry in prechemotherapy and postchemotherapy (at the time of surgery) tumor specimens, and the value of their changes as predictors of relapse-free survival were evaluated by Kaplan-Meier and Cox proportional hazard regression analyses.
Neoadjuvant chemotherapy resulted in a significant reduction in the percentage of cells expressing TopoII (P < 0.0001). No significant change was observed for HER-2. TopoII and HER-2 expression before chemotherapy predicted tumor response to treatment. Changes in TopoII expression after chemotherapy were strongly associated with a poor relapse-free survival (P < 0.0001) in a Cox multivariate analysis adjusted for other clinicopathologic prognostic factors.
Changes in TopoII expression after anthracycline-based neoadjuvant chemotherapy is an independent predictor of a poor relapse-free survival in patients with breast cancer. Tumor cells displaying an increased TopoII expression after treatment may be responsible for relapses, and may, therefore, define a group of patients with anthracycline-resistant breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epirubicin - therapeutic use</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Mastectomy</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - metabolism</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Stereoisomerism</subject><issn>1078-0432</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1KxDAURrNQnHH0FeS-QCFp0qazlMGfgQEXuh9u0hvboW1Ckg6OT29BXZ3Vd_g4V2wtuG4KrmS5YrcpnTgXSnB1w1airqTUWq3Z967D6ZMSeAfZB98nP1LERLDf4xA6BPoKkVLq_QT9BCYSpgx5Hn1MgC5ThIk8tqf5jFMG29Hoc7cowgWWYdvbnCDSgCFR4SIRpDme-zMOd-za4ZDo_o8b9v789LF7LQ5vL_vd46EIlVJFVWnDVaWscW757LDRVotaNsLVlrh2ruQKt5W2hmuBW4625SUKo2RtSMkNe_i1htmM1B5D7EeMl-N_AvkDqERakQ</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Tinari, Nicola</creator><creator>Lattanzio, Rossano</creator><creator>Natoli, Clara</creator><creator>Cianchetti, Ettore</creator><creator>Angelucci, Domenico</creator><creator>Ricevuto, Enrico</creator><creator>Ficorella, Corrado</creator><creator>Marchetti, Paolo</creator><creator>Alberti, Saverio</creator><creator>Piantelli, Mauro</creator><creator>Iacobelli, Stefano</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20060301</creationdate><title>Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival</title><author>Tinari, Nicola ; Lattanzio, Rossano ; Natoli, Clara ; Cianchetti, Ettore ; Angelucci, Domenico ; Ricevuto, Enrico ; Ficorella, Corrado ; Marchetti, Paolo ; Alberti, Saverio ; Piantelli, Mauro ; Iacobelli, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-557b0454cbff337fa87c716381f6ce07ff204a957cb071a90acd02a1b436be43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epirubicin - therapeutic use</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Mastectomy</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - metabolism</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Stereoisomerism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tinari, Nicola</creatorcontrib><creatorcontrib>Lattanzio, Rossano</creatorcontrib><creatorcontrib>Natoli, Clara</creatorcontrib><creatorcontrib>Cianchetti, Ettore</creatorcontrib><creatorcontrib>Angelucci, Domenico</creatorcontrib><creatorcontrib>Ricevuto, Enrico</creatorcontrib><creatorcontrib>Ficorella, Corrado</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Alberti, Saverio</creatorcontrib><creatorcontrib>Piantelli, Mauro</creatorcontrib><creatorcontrib>Iacobelli, Stefano</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tinari, Nicola</au><au>Lattanzio, Rossano</au><au>Natoli, Clara</au><au>Cianchetti, Ettore</au><au>Angelucci, Domenico</au><au>Ricevuto, Enrico</au><au>Ficorella, Corrado</au><au>Marchetti, Paolo</au><au>Alberti, Saverio</au><au>Piantelli, Mauro</au><au>Iacobelli, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>12</volume><issue>5</issue><spage>1501</spage><pages>1501-</pages><issn>1078-0432</issn><abstract>To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy.
Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study. TopoII and HER-2 were measured by immunohistochemistry in prechemotherapy and postchemotherapy (at the time of surgery) tumor specimens, and the value of their changes as predictors of relapse-free survival were evaluated by Kaplan-Meier and Cox proportional hazard regression analyses.
Neoadjuvant chemotherapy resulted in a significant reduction in the percentage of cells expressing TopoII (P < 0.0001). No significant change was observed for HER-2. TopoII and HER-2 expression before chemotherapy predicted tumor response to treatment. Changes in TopoII expression after chemotherapy were strongly associated with a poor relapse-free survival (P < 0.0001) in a Cox multivariate analysis adjusted for other clinicopathologic prognostic factors.
Changes in TopoII expression after anthracycline-based neoadjuvant chemotherapy is an independent predictor of a poor relapse-free survival in patients with breast cancer. Tumor cells displaying an increased TopoII expression after treatment may be responsible for relapses, and may, therefore, define a group of patients with anthracycline-resistant breast cancer.</abstract><cop>United States</cop><pmid>16533774</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-03, Vol.12 (5), p.1501 |
| issn | 1078-0432 |
| language | eng |
| recordid | cdi_pubmed_primary_16533774 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antigens, Neoplasm - metabolism Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cyclophosphamide - therapeutic use Disease-Free Survival DNA Topoisomerases, Type II - metabolism DNA-Binding Proteins - metabolism Drug Resistance, Neoplasm Epirubicin - therapeutic use Female Fluorouracil - therapeutic use Humans Mastectomy Middle Aged Neoadjuvant Therapy Neoplasm Invasiveness - pathology Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - metabolism Neoplasm, Residual - drug therapy Neoplasm, Residual - metabolism Prognosis Receptor, ErbB-2 - metabolism Stereoisomerism |
| title | Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A21%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20of%20topoisomerase%20IIalpha%20expression%20in%20breast%20tumors%20after%20neoadjuvant%20chemotherapy%20predicts%20relapse-free%20survival&rft.jtitle=Clinical%20cancer%20research&rft.au=Tinari,%20Nicola&rft.date=2006-03-01&rft.volume=12&rft.issue=5&rft.spage=1501&rft.pages=1501-&rft.issn=1078-0432&rft_id=info:doi/&rft_dat=%3Cpubmed%3E16533774%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16533774&rfr_iscdi=true |